Focus on knowledge creation

Without ideas there is nothing to manage

The 16th Consortium Meeting was held on 20-21 October 2022 in Barcelona, a 2-day event organised by SYNAPSE that featured the 2nd edition of the eTRANSAFE Awards.

Close to 60 eTRANSAFE consortium members gathered in Barcelona for the second time this year, after the previous face-to-face meeting celebrated in June. Additionally, another 30 project members joined the event remotely, participating through videoconference.

The meeting focused on discussing the progress of the project, which has the goal to improve drug safety predictions. The consortium members had the opportunity to share an overview of the state of activities and agreed upon the prioritization of pending tasks to successfully face the final stretch of eTRANSAFE, scheduled to conclude in February 2023.

One of the meeting highlights was the celebration of the 2nd Edition of the eTRANSAFE Awards ceremony, during which this accolade was granted to selected consortium members for their outstanding contributions to the project.

Winners of the 2nd eTRANSAFE Awards in October 2022 (Barcelona) accompanied by project Academic Coordinator Ferran Sanz (IMIM) who hosted the awards ceremony.

 

In this edition, the EMC crew (Rowan Parry, Erik van Mulligen, Jan Kors, Johan Van Der Lei) was awarded for Outstanding Team Contribution, Manuel Pastor (UPF) for Outstanding Individual Academic Contribution and Gavin Nicholson (Optibrium) for Outstanding Individual Industry Contribution.

Our congratulations to both winners and nominees for this well-deserved recognition, which acknowledges your continuous efforts towards making eTRANSAFE a successful project.

We send a big thank you to all participants for attending this productive event, and look forward to seeing everyone at the next and final eTRANSAFE Consortium Meeting we´ll be organizing in February.

 

About eTRANSAFE

eTRANSAFE is a public-private partnership part of the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) scheme, funded by the European Union’s Horizon 2020 research and innovation programme and EFPIA. The overarching aim of the project is to improve the feasibility and reliability of translational safety assessment during the drug development process by developing an advanced data integration infrastructure together with innovative computational methods.

For more information visit eTRANSAFE website.